CytomX启动贝伐珠单抗I期研究;化疗联合Ib/II期研究拟于2026年底前展开

美股速递
Mar 16

CytomX Therapeutics Inc(简称CytomX)宣布已启动针对贝伐珠单抗的I期临床研究。同时,公司计划在2026年底前开展一项化疗联合疗法的Ib/II期研究。

这两项研究旨在评估候选药物在特定患者群体中的安全性和初步疗效。贝伐珠单抗I期研究将重点关注该药物在晚期实体瘤患者中的耐受性与药代动力学特征。而拟启动的Ib/II期研究则将探索化疗联合方案在特定癌症类型中的治疗潜力。

公司表示,上述进展符合其推进精准肿瘤疗法的战略规划。通过阶段性临床试验,CytomX期望为后续临床开发提供关键数据支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10